Skip to main content
SpringerLink
Log in
Book cover

Allogeneic Stem Cell Transplantation pp 687–694Cite as

Functional Assessment Tools and Co-morbidity Scoring in Hematopoietic Progenitor Cell Transplantation

  • Chapter
  • First Online:

  • 1420 Accesses

Part of the book series: Contemporary Hematology ((CH))

Abstract

Predicting risk of treatment-related toxicities in patients undergoing high dose chemotherapy with progenitor cell support (HDT) has always been an integral part of the decision process for physicians and patients involved in this procedure [1]. Initially when the procedure was used only as salvage therapy for patients with advanced disease performance status and age were the most common factors taken into consideration when deciding whether or not to proceed with high dose chemotherapy [2].

HDT has now become a standard therapy for a variety of malignant and non- malignant disorders, improvements in supportive care as well as novel reduced intensity conditioning regimens have now made HDT a commonly used therapeutic strategy even in patients in the sixth and seventh decades of their life. The increased use of HDT in a more vulnerable patient population has made the transplant community focus more attention on pre-transplant factors that can predict transplant outcomes.

In this chapter, we will summarize the value of current pre-transplant assessment in predicting transplant outcomes, as well as the value of comorbidity scores, and novel ways of measuring transplant toxicities and outcomes.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Thomas ED (1983) Bone marrow transplantation for malignant disease. J Clin Oncol 1:517-531

    PubMed  CAS  Google Scholar 

  2. Thomas ED (1982) The role of bone marrow transplantation for eradication of malignant disease. Cancer 49:1963-1969

    Article  PubMed  CAS  Google Scholar 

  3. Bolwell BJ (2003) Are predictive factors clinically useful in bone marrow transplantation? Bone Marrow Transplant 32:853-861

    Article  PubMed  CAS  Google Scholar 

  4. Fujimaki K, Maruta A, Yoshida M et al (2001) Severe cardiac toxicity in hematological stem cell transplantation: Predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 27:307-310

    Article  PubMed  CAS  Google Scholar 

  5. Hertenstein B, Stefanic M, Schmeiser T et al (1994) Cardiac toxicity of bone marrow transplantation: Predictive value of cardiologic evaluation before transplant. J Clin Oncol 12:998-1004

    PubMed  CAS  Google Scholar 

  6. Jain B, Floreani AA, Anderson JR et al (1996) Cardiopulmonary function and autologous bone marrow transplantation: Results and predictive value for respiratory failure and mortality. The university of Nebraska medical center bone marrow transplantation pulmonary study group. Bone Marrow Transplant 17:561-568

    PubMed  CAS  Google Scholar 

  7. Lehmann S, Isberg B, Ljungman P, Paul C (2000) Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant 26:187-192

    Article  PubMed  CAS  Google Scholar 

  8. Goldberg SL, Klumpp TR, Magdalinski AJ et al (1998) Value of the pretransplant evaluation in predicting toxic 100-day mortality among blood stem cell and bone marrow recipients. J Clin Oncol 16:3796-3802

    PubMed  CAS  Google Scholar 

  9. Chien JW, Madtes DK, Clark JG (2005) Pulmonary function testing prior to hematopoietic stem cell transplantation. Bone Marrow Transplant 35:429-435

    Article  PubMed  CAS  Google Scholar 

  10. McDonald GB, Hinds MS, Fisher LD et al (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118:255-267

    PubMed  CAS  Google Scholar 

  11. Carreras E (2000) Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 64:281-291

    Article  PubMed  CAS  Google Scholar 

  12. Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191-205

    Google Scholar 

  13. Zubrod Cl (1958) Clinical investigations in cancer chemotherapy. J Chronic Dis 8:183-190

    Article  PubMed  CAS  Google Scholar 

  14. Weisdorf D, Bishop M, Dharan B et al (2002) Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: Comparative toxicity and outcomes. Biol Blood Marrow Transplant 8:213-220

    Article  PubMed  Google Scholar 

  15. Robin M, Guardiola P, Dombret H et al (2003) Allogeneic bone marrow transplantation for acute myeloblastic leukemia in remission: Risk factors for long term morbidity and mortality. Bone Marrow Transplant 31:877-887

    Article  PubMed  CAS  Google Scholar 

  16. Deeg HJ, Seidel K, Bruemmer B et al (1995) Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 15:461-468

    PubMed  CAS  Google Scholar 

  17. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 56:221-229

    Article  PubMed  Google Scholar 

  18. Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36:453-471

    Article  PubMed  CAS  Google Scholar 

  19. Extermann M (2000) Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35:181-200

    Article  PubMed  CAS  Google Scholar 

  20. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383

    Article  PubMed  CAS  Google Scholar 

  21. Shahjahan M, Alamo J, de Lima M et al (2004) Effect of comorbidities on allogeneic hematopoietic stem cell transplant outcomes in AML/MDS patients in first complete remission. Biol Blood Marrow Transplant 10(Suppl 2):12-13

    Article  Google Scholar 

  22. Sorror ML, Maris MB, Storer B et al (2004) Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood 104:961-968

    Article  PubMed  CAS  Google Scholar 

  23. Sorror M, Maris M, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919

    Article  PubMed  CAS  Google Scholar 

  24. Artz A, Pollyea D, Kocherginsky M et al (2006) PS and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 12:954-964

    Article  PubMed  Google Scholar 

  25. Sorror ML, Giralt S, Sandmaier B et al (2007) Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood 110:4606-4613

    Article  PubMed  CAS  Google Scholar 

  26. Anderson KO, Giralt SA, Mendoza TR et al (2007) Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 39:759-766

    Article  PubMed  CAS  Google Scholar 

  27. Simmonds MJ, Novy DM, Sandoval R (2005) The influence of pain and fatigue on physical performance and health status in ambulatory patients with HIV. Clin J Pain 21(3):200-206

    Article  PubMed  Google Scholar 

  28. Simmonds MJ (2002) Physical function in patients with cancer. Psychometric characteristics and clinical usefulness of a physical performance test battery. J Pain Symptom Manage 24:404-414

    Article  PubMed  Google Scholar 

  29. Simmonds MJ (2002) The effect of pain and illness on movement: Assessment methods and their meanings. In: Giamberadino M (ed) Pain clinical update. IASP Press, Seattle, pp 179-187

    Google Scholar 

  30. Kinnunen P, Vuolteenaho O, Ruskoaho H (1993) Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 132:1961

    Article  PubMed  CAS  Google Scholar 

  31. Brunner-La Rocca HP, Kaye DM, Woods RL et al (2001) Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 37:1221

    Article  PubMed  CAS  Google Scholar 

  32. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757

    Article  PubMed  CAS  Google Scholar 

  33. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ et al (2004) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 94(6):1881-1887

    Article  Google Scholar 

  34. Kushner I (1982) The phenomenon of the acute phase response. Ann NY Acad Sci 389:39

    Article  PubMed  CAS  Google Scholar 

  35. Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499

    Article  PubMed  Google Scholar 

  36. Fuji S, Kim SW, Fukuda T, Mori S et al (2008) C Reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 14:510-517

    Article  PubMed  CAS  Google Scholar 

  37. Pihusch M, Pihusch R, Fraunberger P et al (2006) Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 76:93-101

    Article  PubMed  CAS  Google Scholar 

  38. Hinguranage A, Goldschmidt H, Cremer FW et al (2006) Preoperative elevation of serum C-reactive protein is predictive for prognosis in myeloma bone disease after surgery. Br J Cancer 95(7):782-787

    Article  Google Scholar 

  39. Armand P, Kim HT, Cutler CS (2007) Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109:4586-4588

    Article  PubMed  CAS  Google Scholar 

  40. Ho GT, Parker A, MacKenzie JF, Morris AJ, Stanley AJ (2004) Abnormal liver function tests following bone marrow transplantation: Aetiology and role of liver biopsy. Eur J Gastroenterol Hepatol 16:157-162

    Article  PubMed  Google Scholar 

  41. Miceli MH, Dong L, Grazziutti ML et al (2006) Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: A study of 367 myeloma patients. Bone Marrow Transplant 37:857-864

    Article  PubMed  CAS  Google Scholar 

  42. Altes A, Remacha AF, Sureda A et al (2002) Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 29:987-989

    Article  PubMed  CAS  Google Scholar 

  43. Majhail N, DeFor T, Lazarus H, Burns L (2008) High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant 14:790-794

    Article  PubMed  CAS  Google Scholar 

  44. Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG (2003) Polymorphisms of IL-1alpha constitute independent risk factors for chronic graft versus host disease following allogeneic bone marrow transplantation. Br J Haematol 122:778-787

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplant and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Sergio Giralt & Uday Popat

Authors
  1. Sergio Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uday Popat
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospitals Case Medical Center, Cleveland, OH, USA

    Hillard M. Lazarus

  2. Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Giralt, S., Popat, U. (2010). Functional Assessment Tools and Co-morbidity Scoring in Hematopoietic Progenitor Cell Transplantation. In: Lazarus, H.M., Laughlin, M.J. (eds) Allogeneic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-478-0_38

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-478-0_38

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-33-6

  • Online ISBN: 978-1-59745-478-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation